DKK4: A Potential Drug Target and Biomarker for Prostate and Lung Cancer

Target Name: DKK4

NCBI ID: G27121

DKK4

DKK4: A Potential Drug Target and Biomarker for Prostate and Lung Cancer

Introduction

Prostate and lung cancer are two of the leading causes of cancer-related deaths worldwide, with increasing incidence rates in both men and women. The development of new treatments and biomarkers for these cancers is crucial for improving patient outcomes. One of the promising targets for cancer research is the Dickkopf-related protein 4 (DKK4), which has been identified as a potential drug target and biomarker for prostate and lung cancer.

DKK4: A Known regulator of cell proliferation and survival

The DKK4 gene, located on chromosome 1p36.1, encodes a protein that plays a critical role in the regulation of cell proliferation and survival. The protein is composed of 195 amino acid residues and has a molecular weight of 21 kDa. DKK4 is a non -protein kinase inhibitor, which means it inhibits the activity of protein kinases, leading to the inhibition of cell proliferation and the stimulation of cell apoptosis.

DKK4 has been shown to play a role in the regulation of cell proliferation and survival in various tissues and organs, including breast, prostate, and lung cancer cells (2, 3). For example, studies have shown that DKK4 is involved in the regulation of cell cycle progression, apoptosis, and angiogenesis (4, 5).

DKK4 as a potential drug target

The identification of DKK4 as a potential drug target is based on its unique mechanism of action and its involvement in the regulation of cell proliferation and survival. One of the main reasons for its potential as a drug target is its behavior as a negative regulator of the PI3K/Akt signaling pathway. This pathway is known for its role in the regulation of cell survival and proliferation, and dysregulation of this pathway has been implicated in the development of various cancers, including prostate and lung cancer.

In recent years, several drugs have been developed and are in clinical trials for the treatment of prostate and lung cancer, targeting PI3K/Akt signaling pathway inhibitors, including DKK4-targeted therapies. For instance, the drug abiraterone, which is a selective inhibitor of the PI3K/Akt signaling pathway, has been shown to reduce the risk of prostate cancer recurrence in men with advanced-stage prostate cancer. Similarly, the drug pazopatinib, which is a PI3K/Akt inhibitor, has been shown to improve survival in patients with advanced-stage lung cancer.

In addition to its potential as a PI3K/Akt inhibitor, DKK4 has also been shown to have other potential drug targets, such as the FGFR signaling pathway, which is known for its role in the regulation of cell growth and survival.

DKK4 as a biomarker

The DKK4 gene has also been shown to have the potential to serve as a biomarker for cancer diagnosis and progression. The expression of DKK4 has been shown to be decreased in various types of cancer, including prostate and lung cancer, and its levels have been used as a biomarker for cancer diagnosis and progression in these cancers (10, 11).

In addition to its potential as a drug target, DKK4 has also been shown to have potential as a biomarker for cancer diagnosis and progression. The expression of DKK4 has been shown to be decreased in various types of cancer, including prostate and lung cancer, and Its levels have been used as a biomarker for cancer diagnosis and progression in these cancers (10, 11).

Conclusion

In conclusion, DKK4 is a promising target for the development of new drugs for the treatment of prostate and lung cancer. Its properties as a negative regulator of the PI3K/Akt signaling pathway and its potential as a drug and biomarker make it an attractive target for cancer research. Further studies are needed to

Protein Name: Dickkopf WNT Signaling Pathway Inhibitor 4

Functions: Antagonizes canonical Wnt signaling by inhibiting LRP5/6 interaction with Wnt and by forming a ternary complex with the transmembrane protein KREMEN that promotes internalization of LRP5/6. DKKs play an important role in vertebrate development, where they locally inhibit Wnt regulated processes such as antero-posterior axial patterning, limb development, somitogenesis and eye formation. In the adult, Dkks are implicated in bone formation and bone disease, cancer and Alzheimer disease (By similarity)

The "DKK4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DKK4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets